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The molecular chaperone heat shock protein 90 alpha (Hsp90𝛼) has been recognized in various tumours including glioma.
This pilot study using a proteomic approach analyses the downstream effects of Hsp90 inhibition using 17-allylamino-17-
demethoxygeldanamycin (17AAG) and a short hairpin RNA (shRNA) oligonucleotide targeting hsp90𝛼 (shhsp90𝛼) in the U87-MG
glioma cell line. Preliminary data coupled with bioinformatic analysis identified several known and unknownHsp90 client proteins
that demonstrated a change in their protein expression after Hsp90 inhibition, signifying an alteration in the canonical pathways of
cell cycle progression, apoptosis, cell invasion, angiogenesis, and metastasis. Members of the glycolysis pathway were upregulated,
demonstrating increased dependency on glycolysis for energy source by the treated glioma cells. Upregulated proteins also include
Hsp70 and members of its family such as Hsp27 and gp96, thereby suggesting the role of Hsp90 co-chaperones in compensating
for Hsp90 function after Hsp90 inhibition. Considering Hsp70’s role in antiapoptosis, it was postulated that a combination therapy
involving a multitarget approach could be carried out. Consequently inhibition of both Hsp90 and Hsp70 in U87-MG glioma cells
resulted in 60% cell death indicating the importance of combination therapy for glioma therapeutics.
1. Introduction
Heat shock protein Hsp90 is upregulated in several tumours
including glioma, and thus targeting its functionmay provide
new therapeutic aspects [1, 2]. Hsp90 is a highly conserved
molecular chaperone present in eukaryotic cytosol. It has
been proposed to play a vital role in tumorigenesis, mainte-
nance of transformation and regulation of several key pro-
teins involved in apoptosis and survival and growth pathways
[3]. These pathways are exploited in tumours where Hsp90
chaperoning contributes towards drug resistance [4], metas-
tasis [5], and cell survival [6].The synthesis of several natural
and chemical inhibitors along with RNA inhibition using
siRNA or shRNA to silence Hsp90 has been undertaken.
Previous studies in our laboratory have shown that
enhanced chemosensitivity is attained upon transcription
inhibition of the inducible Hsp90 subunit hsp90𝛼 by siRNA,
suggesting that inhibiting hsp90𝛼 expression by shRNA could
possibly be a favourable therapeutic approach compared to
conventional chemotherapies as it is target specific and has
reduced toxicity. Furthermore, a combination treatment of
siRNA followed by Temozolomide (TMZ) (200–400𝜇M)
after 48 hours was significantly more effective, suggesting
the combination as a possible effective form of therapy
[7]. Given its functions as a molecular chaperone and its
expression in gliomas, hsp90𝛼 may represent a promising
target for the development of novel therapeutic strategies.
This study investigated Hsp90 chaperone inhibition with (a)
17-allylamino-17-demethoxygeldanamycin (17AAG), an ana-
logue of Geldanamycin (GA) and a potent Hsp90 inhibitor
and (b) short hairpin RNA (shRNA) oligonucleotide targeted
against hsp90𝛼.
In this study, proteins were extracted from the U87-
MG cell lysate to characterize the changes transpired after
Hsp90 inhibition with 17AAG and shRNA (hsp90𝛼) using a
differential proteomic analysis. Proteins expressed in wild-
typeU87-MGcells (control) were comparedwith the proteins
expressed in U87-MG cells upon subsequent silencing of
hsp90𝛼 (U87-MG-shhsp90𝛼) and the proteins expressed in
U87-MG cells after 17AAG treatment (U87-MG-17AAG).
This approach elucidates the changes caused in the
Hsp90 chaperone system after inhibition using 17AAG or
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shRNA oligonucleotide targeting hsp90𝛼 in glioma. Though
the significance of Hsp90’s glioma regulation has been well
documented, the downstream effect of Hsp90 inhibition
at the various physiological and signalling pathways in
glioma is still ambiguous. Silencing hsp90𝛼 at the genetic
level (shRNA) and at the protein level (17AAG) to identify
potential downstream pathways and proteins affected and/or
controlled byHsp90 in glioma is a novel approach.Therefore,
this pilot study aims to silence Hsp90 by using 17AAG
and shRNA targeting hsp90𝛼 and attempts to identify the
potential pathways and proteins altered in glioma.
This study also explores the role of Hsp70 as a co-
chaperon for Hsp90. Hsp70 is the most predominant and
conserved class of the Hsps [8], and it functions as an
antiapoptotic protein [9]. It forms a multichaperone complex
with Hsp90 and is involved in folding and refolding of
newly synthesized or misfolded proteins [9, 10]. Hsp70 with
Hsp90 plays vital roles in tumour immunity by preventing
apoptosis and regulating the generation of stable complexes
with cytoplasmic tumour antigens bestowing antitumour
immunity [11, 12]. In tumours, Hsp70 is upregulated and
plays a key role in the regulation of several pathways such
as cell proliferation, metastasis, invasion, and death [13].
The over expression of Hsp70 has been associated with
poor prognosis, and reduced response to tumour thera-
peutics [14]. Members of the Hsp70 family act at multiple
points in the apoptotic pathway and inhibit cell death [15–
17].
2. Materials and Methods
2.1. Cell Culture. The human brain cell line U87-MG
(glioblastoma) used in this study was purchased from Euro-
pean Collection of Cell Cultures (ECCAC, UK). U87-MG
was cultured in Eagle’s minimum essential medium (EMEM)
(Sigma, UK) and was supplemented with 10% (v/v) foetal
bovine serum (Gibco-BRL, UK) and 2mM L-glutamine
(Sigma, UK). Cells were cultivated in 25 or 75 cm2 culture-
treated polystyrene flasks and were maintained at 37∘C with
5%CO
2
in filtered air. Cells were closelymonitored andwhen
a monolayer growth of 70–80% confluence was obtained, the
cells were scraped and subcultured.
2.2. shRNA Transfection. Purified and sequence verified
pGFP-V-RS expression plasmids with hsp90𝛼 specific shRNA
cassettes were obtained from Origene, USA. The sequence
of the shRNA verified to silence hsp90𝛼 was shRNA
(NM 005348; targeted exon 10 at nucleotides 2137–2166 bp)
(sense) 5󸀠CTCTCAAGGACTACTGCACCAGA3󸀠 (anti-
sense) 5󸀠GAGAGTTCCTGATGACGTGGTCTTACTTC3󸀠.
The shRNA plasmids were diluted with 50𝜇L of dH
2
O to
get a final concentration of 100 ng/𝜇L, from which 1 𝜇g of
the shRNA expression plasmid DNA was then transfected
into the cells according to the manufacturer’s protocol using
MegaTran 1.0 solution. The cells were then incubated in a 5%
CO
2
incubator for 48 hours before being used for further
analysis.
2.3. 17AAG and KNK437 Treatment. 17AAG (InvivoGen,
USA) and KNK437 (Merck Bioscience, UK) were solubilised
in DMSO (Sigma-Aldrich, UK). U87-MG cells were treated
for 48 hours with inhibitory concentration (IC
50
) values
of 17AAG (0.25 𝜇M) and KNK437 (55 nM) (unpublished
results) and then with a combination of IC
50
values of 17AAG
and KNK437. The relative IC
50
values were determined using
point to point analysis. CellTitre-Glo one solution assay
(Promega, UK) was used to determine the percentage of
viable cells present in culture. The assay quantifies the level
of the present ATP which is indicative of the presence of
metabolically active cells. The raw data of the luminescence
units were plotted against the different drug(s) concentration
used, and regression analysis was used to determine the IC
50
of the drug(s).
2.4. Akt/PKB Kinase Activity. The Akt/PKB kinase activity
was assayed using a solid-phase enzyme-linked immune-
absorbent assay kit (Assay Deigns, UK) that detects the
Akt/PKB activity in the solution phase. Proteins were
extracted from the control cells (U87-MG Wild-Type) and
treated cells (U87-MG-17AAG; U87-MG-shhsp90𝛼) using
CelLytic MT mammalian tissue lysis buffer (Sigma, UK).
Bradford’s assay was used to determine the protein con-
centration and, 1 𝜇g of protein from each sample was used
to perform the Akt/PKB kinase activity assay following the
manufacturer’s protocol.
2.5. Flow Cytometry. The control and treated cells (>1 ×
106 cells) were collected by scraping. The cells were washed
3 times with 0.1% bovine serum albumin (BSA) made in
0.1M phosphate buffered saline (PBS). After each wash, the
cells were centrifuged at 1000 rpm for 5min at 4∘C, and
the supernatant was discarded. The cells were permeabilised
by incubating with 0.1% of 0.1M Triton X-100 in PBS for
15min in the dark followed by 3 washes with 0.1% BSA. The
blocking solution (made up with 5% rabbit serum in 0.1M
PBS) was added to the cells and incubated for 30min at
4∘C. The cells were centrifuged and the blocking solution
was discarded, and Hsp90𝛼 specific primary antibody, (rat
monoclonal IgG2a (1 : 50) made up in 5% rabbit serum with
0.1M PBS) was added and incubated for 30min.The primary
antibody was removed after 3 washes with 0.1% BSA. Hsp90𝛼
secondary antibody {rabbit anti-rat IgG conjugated with
fluorescein isothiocyanate (FITC) (1 : 130)} prepared similar
to the primary antibody preparation was added to the cell
sample and incubated in the dark for 30min. The negative
control was prepared by excluding the labelling with primary
antibody. The cells were washed 3 times and resuspended in
0.1% BSA. The cell suspension was filtered to remove clumps
using a sterile filter. The samples were stored at 4∘C in the
dark until being analysed on the flow cytometer. Throughout
the experimental process the samples and the reagents were
kept on ice to minimize cell death. The samples during each
wash were gently pipetted to achieve a single cell suspension.
2.6. Proteomic Analysis. Two-dimensional difference gel
electrophoresis (2D-DIGE) and protein identification (ID)
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were performed by Applied Biomics, Inc (Hayward, CA).
Both the control and treated cell pellets were obtained by
scraping, and the culture medium was removed by washing
the pellets 3 times with washing buffer (10mM Tris-HCl,
5mM magnesium acetate, pH 8.0). Also, 200 𝜇L of 2D cell
lysis buffer (30mM Tris-HCl, pH 8.8, containing 7M urea,
2M thiourea, and 4%CHAPS)was added to 10mgof cultured
cell pellet. The mixture was sonicated at 4∘C followed by
shaking for 30min at room temperature and then centrifuged
for 30min at 14000 rpm. The supernatant was collected, and
Bio-Rad protein assay method was used to measure the
protein concentration.
The protein extracts (∼25–50𝜇g) from the control and
treated U87-MG cell samples were subjected to labelling
using CyDye DIGE fluors (Cy2, Cy3 or Cy5). Proteins
were separated using two-dimensional polyacrylamide gel
electrophoresis (2D-PAGE) under denaturing conditions.
The gels were stained and scanned using Typhoon TRIO
(Amersham BioSciences, US) following protein separation.
Differential regulation amidst the proteins was analyzed
using Image Quant software (Amersham Bioscience, USA)
by merging the images obtained. DeCyder analysis was
performed for automated detection, background subtrac-
tion, quantitation, normalization, and intergel matching
and spot picking. Protein identification was carried out
using a mass spectrometer, in particular Matrix-assisted
laser desorption/ionization-time of flight (MALDI-TOF).
The peptide masses derived from the mass spectrometric
analysis were matched with peptide fingerprints of known
proteins in a protein sequence database using search engine
MASCOT 2.0 (Matrix Science, US).
2.7. Statistical Analysis. All values were expressed as mean ±
standard deviation for three independent experiments. Stu-
dent’s 𝑡-test and paired 𝑡-test were used to test the difference
between the samples. Values of significance between ∗𝑃 <
0.05 and ∗∗𝑃 < 0.001 were considered to be statistically
significant.
3. Results
Hsp90𝛼 inhibition was initially compared by studying the
protein level of Hsp90𝛼 in the control (wild-type U87-MG
cells) and the treated cells with shhsp90𝛼 and 17AAG referred
to as U87-MG-shhsp90𝛼 and U87-MG-17AAG, respectively,
using fluorescence-activated cell sorting (FACS) analysis
with a flow cytometer (Figure 1 and Table 1). These results
demonstrate that both treatments can significantly inhibit the
expression of Hsp90𝛼 in the U87-MG glioma cell line (∗∗𝑃 <
0.001). The results also demonstrate that 17AAG works more
effectively than shRNA.
Previous studies suggested the importance of Hsp90 in
the maintenance of AKT kinase activity [18]; thus correlating
the Hsp90 client protein Akt/PKB kinase activity levels is
indicative to the activity of Hsp90, determined using the
Akt/PKB kinase activity assay kit.
Akt/PKB kinase activity assay kit was used tomeasure the
activity of Akt/PKB kinase in the control (wild-type U87-MG
Table 1: Hsp90 regulation level after silencing in U87-MG cells.
Samples
Kinase
activity for
1 𝜇g Protein
Hsp90𝛼
expression
[%]
U87-MG (Control) 234.51 ± 4 76 ± 0.7
U87-MG-17AAG 44.53 ± 0.1∗∗ 42.7 ± 0.2∗∗
U87-MG-shRNA hsp90𝛼 95.16 ± 1.9∗∗ 64.1 ± 1.4∗∗
Data values are mean ± standard deviation, 𝑛 = 3; ∗𝑃 < 0.05 and ∗∗𝑃 <
0.001 are considered to be statistically significant, with ∗ being significant
and ∗∗ being very significant.
Note: Hsp90 protein levels were determined by FACS analysis, and Akt/PKB
kinase activities were measured in the control (wild-type U87-MG cells),
treated cells (U87-MG-shhsp90𝛼 and U87-MG-17AAG), and its activity.
cells) and treated cells (U87-MG-shhsp90𝛼 and U87-MG-
17AAG) (Table 1). The Akt/PKB kinase activity was signif-
icantly reduced upon inhibition of Hsp90 by 17AAG and
shRNA oligonucleotide targeted against hsp90𝛼. Statistical
analysis using paired-sample 𝑡-test demonstrated ∗∗𝑃 <
0.001 for treated cells compared to untreated cells in U87-MG
cell line showed a significant decrease in Akt kinase activity
after hsp90𝛼 inhibition using 17AAG and shhsp90𝛼. Note that
shhsp90𝛼 was less effective compared to 17AAG.
The U87-MG glioma cells were treated with 17AAG
and transfected with shRNA targeting hsp90𝛼 to inhibit
Hsp90 function. Proteins were isolated from the samples,
and proteomic analysis was carried out. A comprehensive
proteomic study was further performed on the control (wild-
type U87-MG) and the treated (U87-MG-17AAG and U87-
MG-shhsp90𝛼) cell samples using 2D-DIGE and MALDI-
TOFmass spectrometry. Proteomic analysis revealed 96 spots
to be differentially expressed by a volume ratio of 1.5-fold
or greater after treatment across the three samples tested
(Figure 2). The spots were selected upon DeCyder analysis,
and some of the spots were differentially modified between
the three treated groups to show a slight shift in molecular
weights. Mass spectrophotometric analysis was carried out
using MALDI-TOF and for protein identification, and 36
spots showing ≥2-fold change were selected (Table 2). The
protein identification was carried out on the basis of peptide
fingerprint mass mapping (MS data) and peptide fragmen-
tation mapping (tandem mass spectrometry (MS/MS) data).
For the identification of proteins from their primary sequence
databases, MASCOT search engine was used. From the
36 spots identified, 33 were identified as human proteins,
while the other 3 were not elucidated (identified). More
than one spot was identified as the same protein upon
protein identification. This could have been attributed to the
presence of different isoforms of the same protein following
posttranslational modifications such as phosphorylation or
methylation which changes the proteins isoelectric point (pI)
and/or molecular weight (MW) causing the spots to shift
along with protein fragmentation.
TheU87-MG glioma cells were treated with IC
50
values of
17AAG (0.25 𝜇M) andKNK437 (55 nM) and thenwith a com-
bination of IC
50
values of 17AAG and KNK437 (Figure 3).
CellTiter-Glo one solution assay (Promega, UK) was used
(as described previously) to determine the number of viable
4 International Journal of Brain Science
0
100
200
300
400
500
10
2
10
3
10
4
10
5
FITC-A
C
ou
nt
(a)
0
100
200
300
400
500
10
2
10
3
10
4
10
5
FITC-A
C
ou
nt
(b)
0
100
200
300
400
500
10
2
10
3
10
4
10
5
FITC-A
C
ou
nt
(c)
Figure 1: Flow cytometric analysis of control and treated U87-MG cell line for Hsp90𝛼 detection. Hsp90𝛼 antigen is detected with FITC
that conjugated secondary antibody upon flow cytometric analysis; (a) control (wild-type U87-MG cells), (b) U87-MG cells treated with
17AAG, and (c) U87-MG cells treated with shRNA targeted against hsp90𝛼. Overlay image of negative (red) with the positive (blue). These
flow cytometric readings are typical of 3 such different experiments.
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Figure 2: 2D-DIGE protein profile. Representation of the 2D-DIGE gel showing (a) control U87-MG and U87-MG-17AAG and (b) control
U87-MG and U87-MG-shhsp90𝛼. Spots were picked automatically by spots volume ratio ≥2.
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Table 2: Proteins identified by mass spectrophotometry.
Protein Accessionnumber Molecular function Biological process
U87-MG-
17AAG/U87-
MG
U87-MG-
shhsp90𝛼/U87-
MG
Proteins upregulated by inhibition of Hsp90 by 17AAG and shRNA targeted towards hsp90𝛼
HSP70-1 (homosapiens) gi|4529893 Chaperone activity Protein metabolism 7.8 1.3
Hexokinase 1, isoform CRA d
(homosapiens) gi|119574708 Catalytic activity
Metabolism, energy
pathways 4.5 1.9
Tumor rejection antigen (gp96) 1
variant (homosapiens) gi|62088648
Heat shock protein
activity Protein metabolism 3.1 1.7
Vimentin variant 3 (homosapiens) gi|167887751 Structural constituentof cytoskeleton
Cell growth and/or
maintenance 2 1.2
Pyruvate kinase, muscle
(homosapiens) gi|127795697 Kinase activity
Metabolism, energy
pathways 6.6 2.9
Vimentin variant 3 (homosapiens) gi|167887751 Structural constituentof cytoskeleton
Cell growth and/or
maintenance 3.9 1.4
Heat shock 70 kDa protein 8
isoform 2 (homosapiens) gi|24234686
Heat shock protein
activity Protein metabolism 4.2 1.2
Chain A, Crystal Structure of
Aldose Reductase complexed with
Dichlorophenylacetic acid
gi|119390284 Oxidoreductaseactivity
Metabolism, energy
pathway 2.8 1.2
Annexin I (homosapiens) gi|4502101 Calcium ion binding Cell communication,signal transduction 16.8 1.7
Glyceraldehyde-3-phosphate
dehydrogenase (homosapiens) gi|31645 Catalytic activity
Metabolism, energy
pathway 8 1.9
Ubiquitin carboxyl-terminal
Esterase L1 (ubiquitin thiolesterase),
Isoform CRA c (homosapiens)
gi|119613387 Ubiquitin specificprotease activity Protein metabolism 2.2 1
Heat shock protein 27
(homosapiens) gi|662841 Chaperone activity Protein metabolism 2.7 1.1
Heat shock protein 27
(homosapiens) gi|662841 Chaperone activity Protein metabolism 2.7 1.2
Actin related protein 2/3 complex
Subunit 2 (homosapiens) gi|5031599
Cytoskeletal protein
binding
Cytoskeleton
organization and
biogenesis
2.9 1
Heat shock 70 kDa protein 8
isoform 2 variants (homosapiens) gi|62896815
Heat shock protein
activity Protein metabolism 4.5 1.3
Proteins downregulated by inhibition of Hsp90 by 17AAG and shRNA targeted towards hsp90𝛼
X-ray repair complementing
defective repair in Chinese hamster
cells 6 (Ku autoantigen, 70 kDa)
(homosapiens)
gi|169145198 DNA binding
Regulation of
nucleobase,
nucleoside,
nucleotide, and
nucleic acid
metabolism, DNA
repair.
−3.7 −1.2
Vimentin (homosapiens) gi|62414289 Structural constituentof cytoskeleton
Cell growth and/or
maintenance −2.3 −3.4
Vimentin (homosapiens) gi|62414289 Structural constituentof cytoskeleton
Cell growth and/or
maintenance −2.1 −1.3
SERPINE1 mRNA binding protein 1
isoform 1 gi|66346679 RNA binding
Regulation of
nucleobase,
nucleoside,
nucleotide, and
nucleic acid
metabolism.
−2.2 −1.4
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Table 2: Continued.
Protein Accessionnumber Molecular function Biological process
U87-MG-
17AAG/U87-
MG
U87-MG-
shhsp90𝛼/U87-
MG
Calumenin isoform a precursor
(homosapiens) gi|4502551 Calcium ion binding
Cell communication,
Signal transduction −1.9 −2.5
Phosphoglycerate kinase 1
(homosapiens) gi|4505763 Catalytic activity
Metabolism, Energy
pathways −1.2 −2
Aldolase A, fructose-bisphosphate,
isoform CRA b gi|119600342 Lyase activity
Metabolism, Energy
pathways −2 −1.6
Predicted
Glyceraldehyde-3-phosphate
Dehydrogenase-like 6
(homosapiens)
gi|169208088 Catalytic activity Metabolism, Energypathways −2.5 −1.8
Tropomyosin 4-anaplastic
lymphoma kinase fusion protein
(homosapiens)
gi|13274400 Structural constituentof cytoskeleton
Cell communication,
Signal transduction −2 −1.4
Eukaryotic translation initiation
factor 3, subunit 12 gi|10801345
Translation regulator
activity Protein metabolism −2.7 −1.6
Transgelin 2 (homosapiens) gi|4507357 Unknown Unknown −3 −1
Chain A, Cyclophilin B complexed
with (d-(Cholinylester)ser8)-
Cyclosporin
gi|1310882 Unknown Unknown −3.7 −1.8
Proteins differentially expressed by inhibition of Hsp90 by 17AAG and shRNA targeted towards hsp90𝛼
Collagen, type VI, alpha 1 precursor
(homosapiens) gi|87196339
Extracellular matrix
structural constituent
Cell growth and/or
maintenance 2.1 −1.5
Chain A, structure of human
Annexin A2 in the presence Of
calcium ions
gi|56967118 Calcium ion binding Signal transduction,Cell communication 2.1 −1.1
Heat shock protein beta-1
(homosapiens) gi|4504517 Chaperone activity Protein metabolism 2.3 −1.2
Chain A, Human manganese
superoxide dismutase mutant
Q143n
gi|2780818 Superoxide dismutaseactivity
Cell proliferation,
Anti-apoptosis, Cell
growth and/or
maintenance
2.7 −1.2
Chain A, crystal structure of
Ca2+-bound form of Des3-23alg-2 gi|211939086 Unknown Apoptosis 2.3 −1.1
Transgelin 2 (homosapiens) gi|4507357 Unknown Unknown 2.4 −1.1
Note:The lists of identified peptides having≥2-fold change were searched againstMASCOT database for the corresponding proteins. Proteins were categorized
according to their change in expression after treatment with 17AAG and shRNA targeting hsp90𝛼 in U87-MG glioma cell line. Protein name, accession number,
proteinmolecular function, biological function, and fold change (volume ratio treated/control) as generated byMASCOT and human protein research database
are summarized.
cells present. The results show that combining 17AAG and
KNK437 resulted in an increased cell death rate of U87-MG
glioma cells (∗∗𝑃 < 0.001).
4. Discussion
Hsp90 is upregulated in several human cancers, and targeting
its function could be of therapeutic importance [2]. Previous
studies have shown the presence of Hsp90 activity in glioma
cell lines and tissues but not in normal brain cell lines or
tissues [1, 19]. Hsp90 inhibitors exhibit antitumour activity
by binding to Hsp90 and inducing proteosomal degradation
of Hsp90 [20, 21]. As for 17AAG, a benzoquinone antibiotic
derived fromGA is a potentHsp90 inhibitor, it dissociates the
Hsp90 complex and leads to the inactivation of Hsp90 and
eventually results in its degradation [22, 23]. Furthermore, it
has been reported to inhibit tumour growth in cell lines and
it is being examined in preclinical trials [22, 24, 25].
Cohorts of U87-MG cells were treated with 17AAG and
shRNA to target hsp90𝛼 in this study. The Akt/PKB kinase
activity was significantly reduced by 81 and 59.4%, (∗∗𝑃 <
0.001), and the flow cytometric analysis showed a reduction
in Hsp90𝛼 protein levels by approximately 44 and 16% after
17AAG and shhsp90𝛼 treatments, respectively (∗∗𝑃 < 0.001).
The reduction of Akt/PKB kinase protein was in agreement
with previous studies which reported a dose dependent
decrease inHsp90 client proteins, namely, Akt after exposure,
to 17AAG in murine neural stem cells and glioma stem
cells [26]. Based on the previous literature reports and the
laboratory findings, the inhibition of Hsp90 protein is a
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Figure 3: Cell viability assessment of U87-MG with 17AAG and
KNK437.The percentage of viableU87-MGcells after treatmentwith
inhibitors of Hsp90 and Hsp70, 17AAG, and KNK437, respectively,
and a combination of the two. Data values are mean ± standard
deviation, 𝑛 = 3; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 are considered to
be statistically significant.
more effective therapeutic approach than silencing hsp90
gene since 17AAG showed a better silencing profile.
To understand the mechanisms involved or to char-
acterize the changes caused at the cellular protein levels
by inhibition of Hsp90, a differential proteomic analysis
comparing control cells (wild-typeU87-MG) and treated cells
(U87-MG-shhsp90𝛼 and U87-MG-17AAG) was performed.
The 2D-DIGE technique was carried out to separate the
proteins, while MALDI-TOF mass spectrometry was used
for protein identification. Based on a 2-fold cut off, the
analysis identified 36 proteins, while MALDI-TOF analysis
identified 33 proteins with altered expressions showing >
99% confidence levels (3 protein being listed as unknown
proteins).
On Hsp90 inhibition 15 proteins were found to be
upregulated, of which 6 proteins are members of Hsp70
family together with Hsp27 and the gp96 which is a member
of the Hsp90 family. These molecular chaperones serve as
cochaperones to Hsp90 function [27, 28], thereby suggesting
the role of Hsp90 cochaperones in compensating for Hsp90
function after Hsp90 inhibition. However, further research
needs to be carried out to confirm these postulations. Mem-
bers of the glycolysis pathwayswere also upregulated, demon-
strating increased dependency on glycolysis for energy by
the treated glioma cells. This phenomenon is described as
the “Warburgs effect”, and it is an important phenomenon
during malignant transformation [29]. The other proteins
reported to be upregulated were vimentin, aldose reductase
complexedwith dichlorophenoxyacetic acid, annexin 1, ubiq-
uitin thiolesterase isoform CRA d, and actin related protein
2/3 complex subunit 2. Most of the proteins upregulated are
involved in proteinmetabolism, energy pathways, cell growth
and/ormaintenance,metabolism, cell communication, signal
transduction, and cytoskeleton organization and biogenesis.
Their upregulation could be attributed to their functions
whichmay assist U87-MG glioma cells to survive after Hsp90
inhibition. Thus, Hsp90 inhibition may be sublethal, and
there is a need for a multitarget approach to glioma therapy.
As discussed earlier, it was observed that 17AAG inhibits
Hsp90 greater than shRNA targeting hsp90𝛼. A significant
difference between the increase in some of the key pro-
teins, namely, Hsp70-1, Hsc70, hexokinase 1, pyruvate kinase,
GAPDH, and annexin 1 was observed between the two
treatments, that is, 17AAG and shRNA targeting hsp90𝛼.
Several proteins such as Ku autoantigen, vimentin, ser-
pine1 mRNA binding protein 1, calumenin, phosphoglyc-
erate kinase, aldolase A, tropomyosin 4-anaplastic lym-
phoma kinase fusion protein, eukaryotic translation initi-
ation factor 3, transgelin 2, cyclophilin B complexed with
(d-(cholinyester)ser8)-cyclosporin, and GAPDH (predicted)
were downregulated. Some of the proteins downregulated
after Hsp90 inhibition are involved in various cellular
responses such as DNA repair, protein synthesis, and cell
mobility. Most of the proteins downregulated such as Ku70,
SERPINE1, PGK1, and transgelin after Hsp90 inhibition are
normally upregulated in several tumours including gliomas
[30–33]. Thus, their subsequent downregulation after Hsp90
inhibition could be of therapeutic importance. However,
further work should be carried out to understand the
interactions between the downregulated proteins and Hsp90
in the treatment of gliomas. Though certain proteins like
vimentin and GAPDH are present in both upregulated and
downregulated lists of proteins, it could be argued that
they are different isoforms/variants of the protein (as seen
in Table 2) which were possibly altered by negative and/or
positive feedback mechanism and, hence, show presence in
both upregulated and the downregulated lists. Further studies
should be carried out to further understand the mechanism.
Proteomic analysis in this study showed induction of the
Hsp70 family members after Hsp90 inhibition. Therefore, it
can thereby be postulated that inhibition of Hsp70 together
with Hsp90 could be of therapeutic importance in glioma
therapy. Based on this hypothesis, U87-MG glioma cells
were treated with both a Hsp90 inhibitor, that is, 17AAG
and aHsp70 inhibitor, that is, N-formyl-3,4-methylenedioxy-
benzylidene-gamma-butyrolactam (KNK437). KNK437 is a
benzylidene lactam compound which affects the induction of
Hsp70 [34]. In addition toHsp70, KNK437 has a considerable
effect on the activation of the transcription factor, heat shock
factor protein 1 (HSF1) and potentially inhibits the activity of
Hsp40 and Hsp105, however, little is known about KNK437
and its mechanism [34]. This study in the light of previous
finding examined the combined effect of inhibiting Hsp90
and Hsp70 with 17AAG and KNK437, respectively, in U87-
MG glioma cell line.
Members of Hsp70 family act at multiple points in the
apoptotic pathway and inhibit cell death [15–17]. Thus, even
though Hsp90 was inhibited, the induction of Hsp70 after
inhibition could have resulted in survival of the glioma cells
(U87-MG). It can therefore be postulated that the inhibition
of Hsp70 and Hsp90 would be of a therapeutic importance
in glioma therapy. Based on this hypothesis, U87-MG glioma
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cells were treated with both the Hsp90 inhibitor, that is,
17AAG, and the Hsp70 inhibitor, that is, KNK437. The IC
50
level of KNK437 was reported to be 55 nM, after 48 hours
in the U87-MG cell line. Cell viability analysis demonstrated
a higher percentage of U87-MG glioma cell death (∼60%)
(∗∗𝑃 < 0.001) when treated with a combination of 17AAG
and KNK437 compared to treatment with 17AAG alone
which resulted in ∼39% cell death. When U87-MG glioma
cells were treated with only KNK437, there was ∼37% cell
death. However, the effects of 17AAG and KNK437 are not
synergetic but rather additive in nature. Thus, it could be
suggested that combination therapy involving inhibition of
both Hsp90 and Hsp70 could be used for glioma therapy.
5. Conclusion
In conclusion, the pilot study showed that the treatment
of U87-MG glioma cells with 17AAG and shRNA to target
hsp90𝛼, effectively reducedHsp90𝛼 activity and subsequently
reduced the Akt/PKB kinase activity in U87-MG cell line.
These results suggest that inhibition of Hsp90 protein activity
could be applied in the future glioblastoma multiforme
(GBM) therapy.
The efficacy of Hsp90 inhibitors can be compromised
by the induction of antiapoptotic Hsp70 isoforms as an
off-target effect of Hsp90 inhibition. Subsequently, Hsp90
and Hsp70 were both inhibited by treating U87-MG cells
with 17AAG and KNK437, respectively. An induced U87-
MG cell death rate was observed when both Hsp90 and
Hsp70 were simultaneously inhibited. These findings suggest
the applying of a combination therapy in the management
of GBM. We propose a further analysis of the effects of
inhibiting Hsp90 and Hsp70 in combination for glioma
studies. It is equally important to determine the cellular and
subcellular mechanisms, wherebys KNK437 and 17AAG can
induce cell death. Although proteomic screening identifies
useful downstream effects of Hsp90 inhibition, the targets
need further validation. The changes in protein expression
and IPA analysis are indicative of alterations in multiple cell
signalling pathways which need to be investigated.
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